164
Participants
Start Date
October 16, 2020
Primary Completion Date
April 26, 2024
Study Completion Date
May 2, 2024
NIS793
anti-TGFb antibody. NIS793 2100 mg every 2 weeks by intravenous (i.v.) infusion.
Spartalizumab
anti-PD-1 antibody. spartalizumab 400 mg every 4 weeks by i.v. infusion.
gemcitabine
SOC chemotherapy. Gemcitabine (1000 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
nab-paclitaxel
SOC chemotherapy. Nab-paclitaxel (125 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
Novartis Investigative Site, Westmead
Novartis Investigative Site, Melbourne
Novartis Investigative Site, Liège
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Zurich
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Taipei
Univ of Pittsburgh Cancer Institute, Pittsburgh
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Sidney Kimmel CCC At JH, Baltimore
Novartis Investigative Site, Madrid
Winship Cancer Institute, Atlanta
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Verona
Novartis Investigative Site, Taichung
Novartis Investigative Site, Essen
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Paris
Novartis Investigative Site, Ulm
Novartis Investigative Site, Singapore
Novartis Investigative Site, Singapore
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Cente, Boston
Novartis Investigative Site, Vienna
Novartis Investigative Site, Brno
Novartis Investigative Site, Helsinki
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Oxford
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY